Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02147028 : Hippocampal Sparing Whole Brain Radiotherapy vs Conventional Whole Brain Radiotherapy in Patients With Brain Metastases
PhasePhase 2
AgesMin: 16 Years Max: N/A
Eligibility
Inclusion Criteria:

- Age ? 16 years

- Karnofsky Performance Status (KPS) ? 70

- Brain metastases from systemic malignancy which has been histologically confirmed
(from the primary or any metastatic site)

- In total, at most 4 distinct brain metastases based on MRI imaging with contrast at
any prior time-points

- Each of the brain metastases must either be in complete radiological remission on
contrast MRI imaging, or have been treated by neurosurgery or by SRS in line with UK
SRS commissioning guidelines within the following timeframes:

- If treated by neurosurgery only, the patient must be registered within 4 weeks of
the date of neurosurgery (or of the first neurosurgery)

- If treated by SRS only, the patient must be registered within 4 weeks of
treatment to each individual metastasis being completed (i.e. within 4 weeks of
the last SRS fraction to each metastasis)

- If treated by both neurosurgery and SRS, then the patient must be registered
within 6 weeks of the treatment to each individual metastasis being completed
(i.e. within 6 weeks of the neurosurgery and within 6 weeks of the last SRS
fraction to each metastasis)

- Ability to complete NCF test battery (including ability to speak English)

- Willing and able to give consent and to comply with treatment and follow up schedule

Exclusion Criteria:

- Metastases from small cell carcinoma, haematological malignancy, or central nervous
system malignancy

- Leptomeningeal metastases

- Contraindication to MRI imaging with contrast

- Prior radiotherapy to the brain, apart from SRS for brain metastases completed within
6 weeks of trial registration

- Metastases currently or previously within 5 mm of either hippocampus

- Disease specific graded prognostic assessment (DS-GPA) score ? 1.0 for any of the
histologies for which DS-GPA has been defined [Sperduto 2012]

- Women of childbearing potential who are known to be pregnant
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02147028      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740